United States Pharmaceutical Supply Chain Review Act

Bill: 118-s-5206
Sponsor: full_name: Sen. Warren, Elizabeth [D-MA]
Introduced: 2024-09-25
Policy area: Health
Latest action: action_date: 2024-09-25
text: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

Summaries:

tv_txt: II 118th CONGRESS 2d Session S. 5206 IN THE SENATE OF THE UNITED STATES September 25, 2024 Ms. Warren (for herself and Mr. Rubio ) introduced the following bill; which was read twice and referred to the Committee on Banking, Housing, and Urban Affairs A BILL To require a report on foreign investment in the pharmaceutical industry of the United States.

1. Short title This Act may be cited as the United States Pharmaceutical Supply Chain Review Act . 2. Report on foreign investment in pharmaceutical industry (a) In general Not later than 1 year after the date of the enactment of this Act, and annually thereafter, the Federal Trade Commission (in this section referred to as the Commission ), in consultation with the Secretary of Commerce, shall submit to the appropriate congressional committees, the Secretary of Health and Human Services, the Committee on Foreign Investment in the United States, and the Commissioner of Food and Drugs, a report on foreign investment in the pharmaceutical industry of the United States. (b) Elements The report required by subsection (a) shall include an assessment of— (1) the supply chain of the pharmaceutical industry of the United States and the effect of concentration and reliance on foreign manufacturing within that industry; (2) the effect of foreign investment in the pharmaceutical industry of the United States on domestic capacity to produce drugs and active and inactive ingredients of drugs; (3) the effect of foreign investment in technologies or other products for sequencing or storage of DNA, including genome and exome analysis, in the United States, including the effect of such investment on the capacity to sequence or store DNA in the United States; and (4) the effect of pharmaceutical manufacturers in the United States relocating manufacturing facilities to other countries on domestic capacity to produce drugs and active and inactive ingredients of drugs. (c) Authority The Commission shall have authority under section 6 of the Federal Trade Commission Act ( 15 U.S.C. 46 ) to conduct the studies required to prepare the report required by subsection (a). (d) Publication The Commission shall publish an unclassified summary of the report required by subsection (a) on a publicly available internet website of the Commission. (e) Appropriate congressional committees defined In this section, the term appropriate congressional committees means— (1) the Committee on Banking, Housing, and Urban Affairs, the Committee on Health, Education, Labor, and Pensions, the Committee on Armed Services, the Committee on Foreign Relations, the Committee on Commerce, Science, and Transportation, and the Committee on Appropriations of the Senate; and (2) the Committee on Financial Services, the Committee on Energy and Commerce, the Committee on Armed Services, the Committee on Foreign Affairs, and the Committee on Appropriations of the House of Representatives.